Medtronic (NYSE:MDT) said the FDA approved an early trial of its native outflow tract transcatheter pulmonary valve under a new agency program for early feasibility studies.
The TPV device is designed for patients born without a right ventricle-to-pulmonary artery conduit, which provides blood to the lungs, as an alternative to open heart surgery.